Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Venous Thromboembolism: full-pipeline trial registry
17 of 48 indexed Venous Thromboembolism trials are currently recruiting.
Corpus placement: #297 of 28,707 conditions by registered trial count.
48 US clinical trials · 17 currently recruiting · #297 of 28,707 conditions by registered trial count
Venous Thromboembolism: 48 US clinical trials tracked, 17 recruiting.
Venous Thromboembolism is the subject of 48 registered US clinical trials on ClinicalTrials.gov, 17 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 4 of these trials.
Enrollment posture brief
Registry condition venous-thromboembolism
OPEN 17 | RECR 35% | LATE 10 | EARLY 11 | RANK #297 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Pneumonia (35% recruiting · 48 trials)
Venous Thromboembolism lists 17 open slots (35% of 48 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Venous Thromboembolism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Venous Thromboembolism is recruiting below its size-band peers.
17 of 48 indexed trials (35.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Venous Thromboembolism trials is spread across many organizations.
Sanofi accounts for 4 of 48 trials (8.3%). 37 distinct sponsors appear on at least one study for this condition label.
-
Typical Venous Thromboembolism enrolment sits around 480 participants.
Median target enrolment is 480 among the 48 trials that report a genuine target (sentinel values excluded). 12 of those (25%) plan for fewer than 100 participants.
-
Venous Thromboembolism research is mostly interventional.
34 interventional and 14 observational studies make up this index (70.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
48 total, page 1 of 1
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Manuel Monreal
NCT02832245
Evaluation of the SCALED (SCaling AcceptabLE cDs)
University of Minnesota
NCT05628207
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
University of Miami
NCT04295486
Filter Initial & Long Term Evaluation After Placement and Retrieval Registry
Stanford University
NCT01158482
PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism
University of Calgary
NCT05756244
Aspiration Thrombectomy Using the Symphony or Prodigy System
Imperative Care
NCT07350499
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Quercis Pharma
NCT06861088
Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)
Brigham and Women's Hospital
NCT03728166
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Inari Medical
NCT05701917
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Memorial Sloan Kettering Cancer Center
NCT07399977
Warfarin Patient Self-management Implementation in the US Healthcare System
University of Utah
NCT04766216
CLEANer Aspiration for Pulmonary Embolism
Argon Medical Devices
NCT06189313
Supplemental Oxygen in Pulmonary Embolism (SO-PE)
Massachusetts General Hospital
NCT05891886
Apixaban or Enoxaparin After Head and Neck Cancer Surgery
Kiranya Arnold
NCT07189897
Venous Thromboembolism Prevention in Outpatients With Glioma
University of Vermont Medical Center
NCT05683808
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
Medical University of South Carolina
NCT06451003
Glioblastoma Remote Monitoring and Care - Research Protocol
Case Comprehensive Cancer Center
NCT06129760
An Observational Study in the United States to Learn How Venous Thromboembolism, Disseminated Intravascular Coagulation, and Sepsis Are Related
Bayer
NCT06765681
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Anthos Therapeutics
NCT05171075
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
University of Michigan
NCT05351749
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
Regeneron Pharmaceuticals
NCT06299111
Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study
University of California, San Francisco
NCT03292666
Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered
Brigham and Women's Hospital
NCT02969343
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Brigham and Women's Hospital
NCT04736719
Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events
Vanderbilt University Medical Center
NCT04574895
Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events
Thrombosis Research Institute
NCT02155491
Epidemiology of Venous Thromboembolism
Brigham and Women's Hospital
NCT00456196
EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization
Sanofi
NCT00077753
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
Sanofi
NCT00679588
Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
Sanofi
NCT00694382
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
Bayer
NCT00362232
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
Medco Health Solutions
NCT00830570
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
Indiana University
NCT03404635
Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery
Sanofi
NCT00718224
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
Alliance Foundation Trials
NCT02744092
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Washington University School of Medicine
NCT00790335
LEAVE Safe With DOACs
University of Massachusetts, Worcester
NCT04068727
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
University of Colorado, Denver
NCT02366871
Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Medically Ill Patients
University of Utah
NCT00810784
Thrombosis Outcomes in Pediatric Venous Thromboembolism
University of Texas Southwestern Medical Center
NCT03068923
Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients
University of Utah
NCT02687204
Use of Tranexamic Acid in Reduction Mammoplasty
Montefiore Medical Center
NCT04947514
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
University of Utah
NCT03339349
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
Daiichi Sankyo
NCT02303431
The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma
Denver Health and Hospital Authority
NCT01050153
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
Bayer
NCT02309411
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
University of Vermont
NCT01524653
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
New York Medical College
NCT04041843
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 8 |
| Phase 3 | 7 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Venous Thromboembolism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Venous Thromboembolism trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Venous Thromboembolism page
48 registered trials, 17 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 17 Venous Thromboembolism trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sanofi sponsors the most Venous Thromboembolism trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Venous Thromboembolism condition card totals 48 registered trials; most-linked intervention Apixaban; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.